Biocon settles US patent dispute with Roche’s Genentech, eyes 2027 Perjeta biosimilar launch

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech’s patent infringement suit, the New Jersey court dismissed the…

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.